PCSK9 and fatty liver disease: This paradoxical relationship suggests that as liver steatosis progresses, increased PCSK9 secretion into the bloodstream occurs, which subsequently promotes LDL receptor degradation and elevates circulating cholesterol levels, thereby contributing to increased cardiovascular risk in obese populations.